CLASS II ONGOING Drug recall · Reported 28 Oct 2026 · FDA Enforcement Report

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg recalled

Pfizer is recalling Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, distributed nationwide in the US. The recall was initiated on 29 Sep 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 24W07, Exp: 11/30/2026
NDC60793-850, 60793-851, 60793-852, 60793-853, 60793-854, 60793-855
UPC0360793856018, 0360793850016, 0360793852010, 0360793851013, 0360793857015, 0360793853017
Quantity recalled134 1000-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0051-2027
FDA event ID
99963
Recalling firm
Pfizer, Manhattan, NY
Brand
Levoxyl
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Classification
Class II
Status
Ongoing
Recall initiated
29 Sep 2026
FDA classified
16 Oct 2026
Reported
28 Oct 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

29 Sep 2026Recall initiated by company
16 Oct 2026Classified by FDA+17 days
28 Oct 2026Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10

Where it was distributed

US Nationwide and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Which lots are affected?

Lot # 24W07, Exp: 11/30/2026

Where was it sold?

US Nationwide and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 3 Nov 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 99963

This product is part of a recall event; the main page for the event is Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg recalled.

ReportedClassRecallCompanyReasonWhere
CLASS IILevoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg recalledLevoxylPfizerPotency & AssayNationwide

More recalls from Pfizer

All 129

Other Levothyroxine recalls

All 137